Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
about
The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.The effect of an exercise intervention on aerobic fitness, strength and quality of life in children with haemophilia (ACTRN012605000224628).Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialA modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.Outcome measures in haemophilia: more than just factor levels.Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.Health economics of treating haemophilia A with inhibitors.Osteoporosis in haemophilic patient, rehabilitative aspects.A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementGenetic modifications of pigs for medicine and agriculture.Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.Barriers and perceived limitations to early treatment of hemophilia.Prophylaxis in adults with haemophilia.Identifying and overcoming barriers to prophylaxis in the management of haemophilia.Optimizing outcomes for patients with severe haemophilia A.Haemophilia A: meeting the needs of individual patients.Secondary prophylaxis in adolescent and adult haemophiliacs.Physiotherapy treatment in patients with hemophilia and chronic ankle arthropathy: a systematic reviewKey issues in inhibitor management in patients with haemophilia.Joint protection in haemophilia.Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management.Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?Hemophilia and prophylaxis.Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Outcome measures in haemophilia: a systematic review.On-demand treatment in persons with severe haemophilia.Real-world resource use and costs of haemophilia A-related bleeding.Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage - the MUSFIH study.Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia.Social/economic costs and quality of life in patients with haemophilia in Europe.Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era.Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.New images in haemophilia.Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status.Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.Treatment adherence in hemophilia.
P2860
Q30249256-6D545DD7-CFA1-4CFF-ADCD-37773958B4C1Q33245039-134002FD-5C61-4A72-90AD-24669679F03FQ33937275-C46D91C4-C0CF-4729-B0C1-287F9F4A582AQ34011908-F951F829-9C96-4FF8-851C-26FA972B247DQ34737483-504D6117-F7D9-42F5-9068-345519D65F95Q34890523-712F1F81-5D2D-4785-AE70-9084C154CD49Q35676998-E8D97EBF-5B1A-4254-BB5C-30DD16A955EAQ35915662-53223B3A-A941-4E99-B9C6-A18713CE1A57Q36019034-54BA3E25-5C13-4336-835D-AB1F7FB02442Q36283841-7F916E88-D1A4-452A-9D34-6A49E375B9B7Q36333470-B77EA1EF-A3DC-4730-A5C8-FBF473782100Q36369011-9807AD82-87C7-44BB-B0C3-239DBA494EC1Q36466394-D04B2870-C0E6-41F2-941D-40CA4FD1EC99Q36473108-CE6B287B-8C49-4C1F-8053-B9298F16A99EQ36863077-54EA4CF0-57C7-45F2-B197-6C24D833B523Q36904925-30E46A6C-0CD4-48C8-8311-25BBB6E11BA0Q36904929-CAAC134E-72FC-49B9-851A-092965DEB849Q36932769-ECE8341F-F59F-4AE6-9280-9BF9D7BEDACDQ37008132-C7ECDF25-FD84-47F4-A25D-1D241AE04223Q37119647-7904E18E-1431-4ED1-8746-81B271360BE0Q37122401-6BDBD31E-CF9E-4D03-9A96-464B504C5382Q37602415-6E2BF702-ED7F-4B51-93DC-78A13F1EBBFDQ37912258-5FEBBE6E-1699-46A8-A047-EC5881794F4AQ37952373-4AAA037A-82C6-47B6-A833-CFEF934DDC98Q38044472-C4991118-8532-4B0B-88F9-4EC8A0BEB728Q38056467-1B44C37A-A6F7-4B69-B5E9-BF7518E9B90EQ38070822-F40F68A5-261A-439C-A9E9-372710AEB65CQ38205211-26609CEF-E3E9-4B34-8048-9D3970D776BFQ38222571-ADF2BDAE-BC38-4B6D-99C4-0C3534CA2271Q38222575-81BCDCEE-4691-4E11-9C14-6BED235F1A42Q38675749-873F5B73-5C37-430A-B3C7-95835B00AF36Q38749122-F11F4B9E-E8A9-49F6-93F5-FA892DAB76E3Q38843540-6D12BCE8-E23D-4FD5-BF02-FAE428CAADA1Q38885402-DA754AAA-646A-43A6-914D-155E1416C2A1Q38942895-A30AB2D8-7E76-4622-9D40-B7DE3F9C336BQ39019405-88923286-5161-49FF-89DC-8798CFB8A55DQ39847971-7185AE56-D0AB-47FC-A735-E4EEAD5BF3CFQ40261649-6B75C823-5318-45BC-AFCC-B732FA864CD5Q40854812-40506C8F-734D-40D8-81EF-47D320DFB736Q42371331-5A70DA93-849F-40E0-AF02-3DE3B1AC4160
P2860
Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prophylactic versus on-demand ...... f costs and long-term outcome.
@en
Prophylactic versus on-demand ...... f costs and long-term outcome.
@nl
type
label
Prophylactic versus on-demand ...... f costs and long-term outcome.
@en
Prophylactic versus on-demand ...... f costs and long-term outcome.
@nl
prefLabel
Prophylactic versus on-demand ...... f costs and long-term outcome.
@en
Prophylactic versus on-demand ...... f costs and long-term outcome.
@nl
P2093
P2860
P50
P1433
P1476
Prophylactic versus on-demand ...... of costs and long-term outcome
@en
P2093
D E Grobbee
E P Mauser-Bunschoten
G Roosendaal
H M van den Berg
P De Kleijn
P2860
P304
P356
10.1046/J.1365-2516.2002.00695.X
P577
2002-11-01T00:00:00Z